Lexology October 31, 2024
DLA Piper

In this two-part article, we delve into the complexities of gene editing in plants and the ongoing EU legislative debates, followed by an exploration of gene drives and their regulatory challenges. Part 1 examines the legal status of gene-edited plants under EU law and the European Commission’s recent proposal for a new regulation, while Part 2 focuses on the broader implications of gene drives, highlighting both national and international legislative frameworks and future regulatory considerations.

Part 1: Gene editing use in plants

Some 9,000 to 11,000 years ago, humans began to cultivate plants, selecting those with desirable characteristics and using their seeds for future harvests. Today, so called New Genomic Techniques (NGTs), a term used to describe innovative gene editing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?

Share This Article